Skip to main content
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
Published Web Location
http://europepmc.org/articles/PMC3397213?pdf=renderNo data is associated with this publication.
Abstract
Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)-targeted agents has antitumor activity; these data indicate certain patients with HER
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.